BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26884374)

  • 1. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.
    Teira P; Battiwalla M; Ramanathan M; Barrett AJ; Ahn KW; Chen M; Green JS; Saad A; Antin JH; Savani BN; Lazarus HM; Seftel M; Saber W; Marks D; Aljurf M; Norkin M; Wingard JR; Lindemans CA; Boeckh M; Riches ML; Auletta JJ
    Blood; 2016 May; 127(20):2427-38. PubMed ID: 26884374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
    Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
    Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
    Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
    Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
    Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
    Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Ramanathan M; Teira P; Battiwalla M; Barrett J; Ahn KW; Chen M; Green J; Laughlin M; Lazarus HM; Marks D; Saad A; Seftel M; Saber W; Savani B; Waller EK; Wingard J; Auletta JJ; Lindemans CA; Boeckh M; Riches ML
    Bone Marrow Transplant; 2016 Aug; 51(8):1113-20. PubMed ID: 27042847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Schäfer P; Hinke A; Zander AR
    Br J Haematol; 2001 Jun; 113(4):1060-71. PubMed ID: 11442503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children.
    Jeljeli M; Guérin-El Khourouj V; Porcher R; Fahd M; Leveillé S; Yakouben K; Ouachée-Chardin M; LeGoff J; Cordeiro DJ; Pédron B; Baruchel A; Dalle JH; Sterkers G
    Br J Haematol; 2014 Jul; 166(2):229-39. PubMed ID: 24702221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
    Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
    Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation.
    Varanasi PR; Ogonek J; Luther S; Dammann E; Stadler M; Ganser A; Borchers S; Hambach L; Weissinger EM
    PLoS One; 2019; 14(3):e0213739. PubMed ID: 30889204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia].
    Lin X; Ou Y; Long H; Huang Y; Song C; Lu Z; Guo K; Wu B; Xu J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):107-10. PubMed ID: 26875578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients.
    Park M; Lee YH; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Baek HJ; Kook H; Hwang TJ; Lee JM; Hah JO; Lim YJ; Park JE; Lyu CJ; Lim YT; Chong SY; Oh D;
    Ann Hematol; 2015 Mar; 94(3):481-9. PubMed ID: 25417830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.